Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.

SLV306, a potent neutral endopeptidase (NEP) inhibitor with additional endothelin-converting enzyme (ECE)-inhibitory activity, in doses of 200, 400, and 800 mg reduced pulmonary and right atrial pressures, although there was not a clear dose response. Systemic blood pressure, heart rate, and cardiac output were unaffected. SLV306 increased plasma natriuretic peptides and big endothelin-1 levels in a dose-dependent manner, confirming NEP and ECE inhibition.

Radical treatment of organ-localized and locally advanced prostate cancer in Norway--an overview.

In 1998, 28.5% of diagnosed prostate cancer patients in Norway were aged < 71 years and had organ-localized disease and 74.5% of prostate cancer patients aged < 71 years had organ-localized disease.